In response to a Congressional request, OIG examined the 1,510 brand-name drugs with Part D reimbursement and rebates in every year from 2011 to 2015. Specifically, we analyzed: (1) how total Part D reimbursement compared to rebate-adjusted reimbursement from 2011 to 2015; (2) how the size of the rebates changed over the 5 years; and (3) whether rebates grew in tandem with reimbursement across the 5 years (i.e., did rebates increase or decrease at the same level as reimbursement). Focusing solely on brand-name drugs with rebates in every year from 2011 to 2015, per the request, resulted in the exclusion of 45 percent of brand-name drugs with Part D reimbursement across all 5 years. In other words, 45 percent of brand-name drugs did not have rebates in every year from 2011 to 2015. We provide information about these brand-name drugs without rebates across all 5 years in Appendix A. We provide the details of our methodology in Appendix B.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)